{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T18:17:45Z","timestamp":1787249865102,"version":"build-2736575974"},"reference-count":143,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022720","name":"Fondazione Regionale per la Ricerca Biomedica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022720","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009703","name":"Fondazione per la Ricerca Biomedica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009703","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009882","name":"Regione Lombardia","doi-asserted-by":"publisher","award":["3433068"],"award-info":[{"award-number":["3433068"]}],"id":[{"id":"10.13039\/501100009882","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.biopha.2025.117862","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T11:04:49Z","timestamp":1737543889000},"page":"117862","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["An update on drug repurposing in Parkinson\u2019s disease: Preclinical and clinical considerations"],"prefix":"10.1016","volume":"183","author":[{"given":"Michela","family":"Salvad\u00e8","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"DiLuca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Gardoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.biopha.2025.117862_bib1","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/jphp.13273","article-title":"Drug repositioning: a brief overview","volume":"72","author":"Jourdan","year":"2020","journal-title":"J. Pharm. Pharmacol."},{"issue":"11","key":"10.1016\/j.biopha.2025.117862_bib2","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1136\/jnnp-2019-320879","article-title":"Drug repurposing in neurological diseases: an integrated approach to reduce trial and error","volume":"90","author":"Clout","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.biopha.2025.117862_bib3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/bs.pmbts.2024.03.029","article-title":"Reimagining old drugs with new tricks: mechanisms, strategies and notable success stories in drug repurposing for neurological diseases","volume":"205","author":"Rani","year":"2024","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.biopha.2025.117862_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2021.104851","article-title":"In silico methods and tools for drug discovery","volume":"137","author":"Shaker","year":"2021","journal-title":"Comput. Biol. Med."},{"issue":"6","key":"10.1016\/j.biopha.2025.117862_bib5","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00702-023-02641-6","article-title":"Parkinson\u2019s disease therapy: what lies ahead?","volume":"130","author":"Wolff","year":"2023","journal-title":"J. Neural Transm."},{"issue":"6","key":"10.1016\/j.biopha.2025.117862_bib6","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and treatment of parkinson disease: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"issue":"9949","key":"10.1016\/j.biopha.2025.117862_bib7","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S0140-6736(14)60683-8","article-title":"Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson\u2019s disease (PD MED): a large, open-label, pragmatic randomised trial","volume":"384","author":"PD MED Collaborative Group","year":"2014","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.biopha.2025.117862_bib8","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/mds.27372","article-title":"International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson\u2019s disease","volume":"33","author":"Fox","year":"2018","journal-title":"Mov. Disord."},{"issue":"10","key":"10.1016\/j.biopha.2025.117862_bib9","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJM198209023071010","article-title":"Amantadine as an antiviral agent in influenza","volume":"307","author":"Douglas","year":"1982","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.biopha.2025.117862_bib10","doi-asserted-by":"crossref","DOI":"10.4236\/ojd.2017.62004","article-title":"Monoamine oxidase inhibitors\u2014revisiting a therapeutic principle","volume":"6","author":"Entzeroth","year":"2017","journal-title":"Open J. Depress"},{"issue":"5","key":"10.1016\/j.biopha.2025.117862_bib11","doi-asserted-by":"crossref","DOI":"10.1517\/13543784.8.5.697","article-title":"Ropinirole in the treatment of Parkinson\u2019s disease","volume":"8","author":"Zesiewicz","year":"1999","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"3","key":"10.1016\/j.biopha.2025.117862_bib12","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0022-3565(24)38068-1","article-title":"Biochemical and electrophysiological studies on the mechanism of action of PNU-151774E, a novel antiepileptic compound","volume":"288","author":"Salvati","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2025.117862_bib13","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0022-3565(24)37430-0","article-title":"Preclinical evaluation of PNU-151774E as a novel anticonvulsant","volume":"285","author":"Fariello","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.biopha.2025.117862_bib14","doi-asserted-by":"crossref","first-page":"842","DOI":"10.2337\/dc06-2011","article-title":"Type 2 diabetes and the risk of Parkinson\u2019s disease","volume":"30","author":"Hu","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2025.117862_bib15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.nbd.2015.04.008","article-title":"The role of type 2 diabetes in neurodegeneration","volume":"84","author":"Verdile","year":"2015","journal-title":"Neurobiol. Dis."},{"issue":"3","key":"10.1016\/j.biopha.2025.117862_bib16","first-page":"775","article-title":"The association between Type 2 diabetes mellitus and Parkinson\u2019s disease","volume":"10","author":"Cheong","year":"2020","journal-title":"J. Park. Dis."},{"issue":"8","key":"10.1016\/j.biopha.2025.117862_bib17","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1002\/mds.29122","article-title":"The impact of Type 2 diabetes in Parkinson\u2019s disease","volume":"37","author":"Athauda","year":"2022","journal-title":"Mov. Disord."},{"issue":"18","key":"10.1016\/j.biopha.2025.117862_bib18","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003549","article-title":"Risk of Parkinson disease in diabetes mellitus: an updated meta-analysis of population-based cohort studies","volume":"95","author":"Yue","year":"2016","journal-title":"Medicine"},{"issue":"19","key":"10.1016\/j.biopha.2025.117862_bib19","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1113\/JP276149","article-title":"Insulin transport across the blood-brain barrier can occur independently of the insulin receptor","volume":"596","author":"Rhea","year":"2018","journal-title":"J. Physiol."},{"issue":"2","key":"10.1016\/j.biopha.2025.117862_bib20","first-page":"259","article-title":"High prevalence of undiagnosed insulin resistance in non-diabetic subjects with Parkinson\u2019s disease","volume":"8","author":"Hogg","year":"2018","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.biopha.2025.117862_bib21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.parkreldis.2020.08.018","article-title":"Peripheral insulin and amylin levels in Parkinson\u2019s disease","volume":"79","author":"S\u00e1nchez-G\u00f3mez","year":"2020","journal-title":"Park. Relat. Disord."},{"issue":"3","key":"10.1016\/j.biopha.2025.117862_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/cells9030740","article-title":"Insulin resistance promotes Parkinson\u2019s disease through aberrant expression of \u03b1-synuclein, mitochondrial dysfunction, and deregulation of the polo-like kinase 2 signaling","volume":"9","author":"Hong","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2025.117862_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2021.135754","article-title":"Therapies modulating insulin resistance in Parkinson\u2019s disease: a cross talk","volume":"749","author":"Sharma","year":"2021","journal-title":"Neurosci. Lett."},{"issue":"6","key":"10.1016\/j.biopha.2025.117862_bib24","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of Incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.biopha.2025.117862_bib25","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"issue":"9548","key":"10.1016\/j.biopha.2025.117862_bib26","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.biopha.2025.117862_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.00178","article-title":"GLP-1 analogs and DPP-4 inhibitors in Type 2 diabetes therapy: review of head-to-head clinical trials","volume":"11","author":"Gilbert","year":"2020","journal-title":"Front. Endocrinol."},{"issue":"6","key":"10.1016\/j.biopha.2025.117862_bib28","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s40262-018-0728-4","article-title":"Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue, oral semaglutide, in healthy subjects and subjects with Type 2 diabetes","volume":"58","author":"Granhall","year":"2019","journal-title":"Clin. Pharmacokinet."},{"issue":"6706","key":"10.1016\/j.biopha.2025.117862_bib29","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1126\/science.adn4128","article-title":"The benefits of GLP-1 drugs beyond obesity","volume":"385","author":"Drucker","year":"2024","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.biopha.2025.117862_bib30","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3390\/ph17020199","article-title":"Glucagon-like Peptide-1 receptor agonists associated gastrointestinal adverse events: a cross-sectional analysis of the national institutes of health all of Us cohort","volume":"17","author":"Aldhaleei","year":"2024","journal-title":"Pharmceuticals"},{"issue":"3","key":"10.1016\/j.biopha.2025.117862_bib31","first-page":"337","article-title":"Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson\u2019s disease","volume":"4","author":"Aviles-Olmos","year":"2014","journal-title":"J. Park. Dis."},{"issue":"10103","key":"10.1016\/j.biopha.2025.117862_bib32","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.biopha.2025.117862_bib33","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/ejn.14096","article-title":"Post hoc analysis of the exenatide-PD trial\u2014factors that predict response","volume":"49","author":"Athauda","year":"2019","journal-title":"Eur. J. Neurosci."},{"issue":"1","key":"10.1016\/j.biopha.2025.117862_bib34","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S1474-4422(23)00378-2","article-title":"Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial","volume":"23","author":"McGarry","year":"2024","journal-title":"Lancet Neurol."},{"issue":"13","key":"10.1016\/j.biopha.2025.117862_bib35","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","article-title":"Trial of Lixisenatide in Early Parkinson\u2019s disease","volume":"390","author":"Meissner","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.117862_bib36","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2202-13-33","article-title":"Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis","volume":"13","author":"Hunter","year":"2012","journal-title":"BMC Neurosci."},{"issue":"5","key":"10.1016\/j.biopha.2025.117862_bib37","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.drudis.2016.01.013","article-title":"The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson\u2019s disease: mechanisms of action","volume":"21","author":"Athauda","year":"2016","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.biopha.2025.117862_bib38","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40290-020-00374-5","article-title":"Repurposing GLP-1 receptor agonists for Parkinson\u2019s disease: current evidence and future opportunities","volume":"35","author":"Victorino","year":"2021","journal-title":"Pharm. Med."},{"issue":"9","key":"10.1016\/j.biopha.2025.117862_bib39","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1002\/mds.26734","article-title":"Reduced incidence of Parkinson\u2019s disease after dipeptidyl peptidase-4 inhibitors-A nationwide case-control study","volume":"31","author":"Svenningsson","year":"2016","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"issue":"1","key":"10.1016\/j.biopha.2025.117862_bib40","doi-asserted-by":"crossref","first-page":"22489","DOI":"10.1038\/s41598-023-49870-z","article-title":"Use of dipeptidyl peptidase-4 inhibitors was associated with a lower risk of Parkinson\u2019s disease in diabetic patients","volume":"13","author":"Lin","year":"2023","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.biopha.2025.117862_bib41","doi-asserted-by":"crossref","DOI":"10.21037\/atm.2018.04.41","article-title":"DPP-4 inhibitors: a promising therapeutic approach against Alzheimer\u2019s disease","volume":"6","author":"Angelopoulou","year":"2018","journal-title":"Ann. Transl. Med."},{"issue":"9","key":"10.1016\/j.biopha.2025.117862_bib42","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-017-4342-z","article-title":"The mechanisms of action of metformin","volume":"60","author":"Rena","year":"2017","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.biopha.2025.117862_bib43","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41574-023-00833-4","article-title":"Metformin: update on mechanisms of action and repurposing potential","volume":"19","author":"Foretz","year":"2023","journal-title":"Nat. Rev. Endocrinol."},{"issue":"6","key":"10.1016\/j.biopha.2025.117862_bib44","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.parkreldis.2012.03.010","article-title":"Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson\u2019s disease occurring with Type 2 diabetes in a Taiwanese population cohort","volume":"18","author":"Wahlqvist","year":"2012","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.biopha.2025.117862_bib45","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.pnpbp.2017.06.002","article-title":"Effects of metformin exposure on neurodegenerative diseases in elderly patients with type 2 diabetes mellitus","volume":"79","author":"Kuan","year":"2017","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"7","key":"10.1016\/j.biopha.2025.117862_bib46","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-024954","article-title":"Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus","volume":"9","author":"Shi","year":"2019","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.biopha.2025.117862_bib47","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/j.1532-5415.2012.03916.x","article-title":"Metformin, other antidiabetic drugs, and risk of Alzheimer\u2019s disease: a population-based case\u2013control study","volume":"60","author":"Imfeld","year":"2012","journal-title":"J. Am. Geriatr. Soc."},{"issue":"10","key":"10.1016\/j.biopha.2025.117862_bib48","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.2337\/dc13-0229","article-title":"Increased risk of cognitive impairment in patients with diabetes is associated with metformin","volume":"36","author":"Moore","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2025.117862_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.101979","article-title":"Antidiabetic agents as a novel treatment for Alzheimer\u2019s and Parkinson\u2019s disease","volume":"89","author":"Nowell","year":"2023","journal-title":"Ageing Res. Rev."},{"issue":"12","key":"10.1016\/j.biopha.2025.117862_bib50","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S1474-4422(16)30230-7","article-title":"The epidemiology of Parkinson\u2019s disease: risk factors and prevention","volume":"15","author":"Ascherio","year":"2016","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.biopha.2025.117862_bib51","doi-asserted-by":"crossref","first-page":"fcae195","DOI":"10.1093\/braincomms\/fcae195","article-title":"Statin use and risk of Parkinson\u2019s disease among older adults in Japan: a nested case-control study using the longevity improvement and fair evidence study","volume":"6","author":"Ge","year":"2024","journal-title":"Brain Commun."},{"issue":"10","key":"10.1016\/j.biopha.2025.117862_bib52","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/aje\/kwj283","article-title":"Serum cholesterol levels and the risk of Parkinson\u2019s disease","volume":"164","author":"de Lau","year":"2006","journal-title":"Am. J. Epidemiol."},{"issue":"21","key":"10.1016\/j.biopha.2025.117862_bib53","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1212\/01.wnl.0000312511.62699.a8","article-title":"Total cholesterol and the risk of Parkinson disease","volume":"70","author":"Hu","year":"2008","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.biopha.2025.117862_bib54","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/mds.27413","article-title":"Higher serum cholesterol and decreased Parkinson\u2019s disease risk: a statin-free cohort study","volume":"33","author":"Rozani","year":"2018","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"issue":"1","key":"10.1016\/j.biopha.2025.117862_bib55","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12944-020-01284-w","article-title":"A systematic review and meta-analysis of serum cholesterol and triglyceride levels in patients with Parkinson\u2019s disease","volume":"19","author":"Fu","year":"2020","journal-title":"Lipids Health Dis."},{"issue":"6","key":"10.1016\/j.biopha.2025.117862_bib56","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/mds.27006","article-title":"Statins may facilitate Parkinson\u2019s disease: insight gained from a large, national claims database","volume":"32","author":"Liu","year":"2017","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"10.1016\/j.biopha.2025.117862_bib57","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.parkreldis.2022.02.011","article-title":"Association between statin use and Parkinson\u2019s disease in Korean patients with hyperlipidemia","volume":"97","author":"Kim","year":"2022","journal-title":"Park. Relat. Disord."},{"issue":"7","key":"10.1016\/j.biopha.2025.117862_bib58","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/mds.27681","article-title":"Association of statin use with Parkinson\u2019s disease: dose-response relationship","volume":"34","author":"Jeong","year":"2019","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"issue":"5","key":"10.1016\/j.biopha.2025.117862_bib59","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/mds.29349","article-title":"Statin use and incidence of Parkinson\u2019s disease in women from the french E3N cohort study\u2019","volume":"38","author":"Nguyen","year":"2023","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"issue":"4","key":"10.1016\/j.biopha.2025.117862_bib60","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/ana.24751","article-title":"Statin therapy prevents the onset of Parkinson disease in patients with diabetes","volume":"80","author":"Lin","year":"2016","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.biopha.2025.117862_bib61","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/ene.14542","article-title":"Pioglitazone and statins lower incidence of Parkinson disease in patients with diabetes mellitus","volume":"28","author":"Chang","year":"2021","journal-title":"Eur. J. Neurol."},{"issue":"5","key":"10.1016\/j.biopha.2025.117862_bib62","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/mds.28474","article-title":"A double-blind, randomized, controlled trial of Lovastatin in early-stage Parkinson\u2019s disease","volume":"36","author":"Lin","year":"2021","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"issue":"4","key":"10.1016\/j.biopha.2025.117862_bib63","first-page":"545","article-title":"Simvastatin as a potential disease-modifying therapy for patients with Parkinson\u2019s disease: rationale for clinical trial, and current progress","volume":"7","author":"Carroll","year":"2017","journal-title":"J. Park. Dis."},{"issue":"12","key":"10.1016\/j.biopha.2025.117862_bib64","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/jamaneurol.2022.3718","article-title":"Evaluation of Simvastatin as a disease-modifying treatment for patients with Parkinson disease: a randomized clinical trial","volume":"79","author":"Stevens","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.biopha.2025.117862_bib65","doi-asserted-by":"crossref","first-page":"1057083","DOI":"10.3389\/fphar.2022.1057083","article-title":"Recent developments of phosphodiesterase inhibitors: clinical trials, emerging indications and novel molecules","volume":"13","author":"Bondarev","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2025.117862_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105078","article-title":"Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders","volume":"160","author":"Bhat","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"3","key":"10.1016\/j.biopha.2025.117862_bib67","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0031-6989(83)80017-4","article-title":"Therapeutic use of a selective cAMP phosphodiesterase inhibitor (Rolipram) in Parkinson\u2019s disease","volume":"15","author":"Casacchia","year":"1983","journal-title":"Pharmacol. Res. Commun."},{"issue":"6","key":"10.1016\/j.biopha.2025.117862_bib68","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1212\/WNL.0000000000004201","article-title":"Loss of phosphodiesterase 4 in Parkinson disease","volume":"89","author":"Niccolini","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.biopha.2025.117862_bib69","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.parkreldis.2019.02.027","article-title":"The role of phosphodiesterase 4 in excessive daytime sleepiness in Parkinson\u2019s disease","volume":"77","author":"Wilson","year":"2020","journal-title":"Park. Relat. Disord."},{"issue":"10","key":"10.1016\/j.biopha.2025.117862_bib70","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1002\/mds.28686","article-title":"The emerging role of phosphodiesterases in movement disorders","volume":"36","author":"Erro","year":"2021","journal-title":"Mov. Disord."},{"key":"10.1016\/j.biopha.2025.117862_bib71","doi-asserted-by":"crossref","first-page":"7002","DOI":"10.1212\/WNL.0000000000208227","article-title":"Phosphodiesterase-5 inhibitor use is associated with a 60\u201361% relative decrease in the rate of Parkinson\u2019s disease: a cohort study supporting the need for a phase three clinical trial (P11-9.003)","volume":"102","author":"Henry","year":"2024","journal-title":"Neurology"},{"issue":"17","key":"10.1016\/j.biopha.2025.117862_bib72","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1212\/WNL.0000000000004568","article-title":"Caffeine as symptomatic treatment for Parkinson disease (Caf\u00e9-PD): a randomized trial","volume":"89","author":"Postuma","year":"2017","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.biopha.2025.117862_bib73","doi-asserted-by":"crossref","first-page":"21258","DOI":"10.1038\/s41598-024-71922-1","article-title":"Drug repurposing for Parkinson\u2019s disease by biological pathway based edge-weighted network proximity analysis","volume":"14","author":"Han","year":"2024","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.biopha.2025.117862_bib74","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/wsbm.1337","article-title":"In silico methods for drug repurposing and pharmacology","volume":"8","author":"Hodos","year":"2016","journal-title":"\u2019Wiley Interdiscip. Rev. Syst. Biol. Med."},{"key":"10.1016\/j.biopha.2025.117862_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115809","article-title":"High-throughput screening as a drug repurposing strategy for poor outcome subgroups of pediatric B-cell precursor Acute Lymphoblastic Leukemia","volume":"217","author":"Oikonomou","year":"2023","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.biopha.2025.117862_bib76","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/pds.5176","article-title":"Using artificial intelligence to identify anti-hypertensives as possible disease modifying agents in Parkinson\u2019s disease","volume":"30","author":"Visanji","year":"2021","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.biopha.2025.117862_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116442","article-title":"Artificial intelligence-driven drug repositioning uncovers efavirenz as a modulator of \u03b1-synuclein propagation: Implications in Parkinson\u2019s disease","volume":"174","author":"Kim","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"5","key":"10.1016\/j.biopha.2025.117862_bib78","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1007\/s11030-023-10708-5","article-title":"Repositioning the existing drugs for neuroinflammation: a fusion of computational approach and biological validation to counter the Parkinson\u2019s disease progression","volume":"28","author":"Tiwari","year":"2024","journal-title":"Mol. Divers."},{"key":"10.1016\/j.biopha.2025.117862_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2024.109880","article-title":"Using artificial intelligence to identify drugs for repurposing to treat l-DOPA-induced dyskinesia","volume":"248","author":"Johnston","year":"2024","journal-title":"Neuropharmacology"},{"issue":"8","key":"10.1016\/j.biopha.2025.117862_bib80","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41576-022-00466-9","article-title":"Human organs-on-chips for disease modelling, drug development and personalized medicine","volume":"23","author":"Ingber","year":"2022","journal-title":"Nat. Rev. Genet."},{"issue":"3","key":"10.1016\/j.biopha.2025.117862_bib81","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.jcf.2023.03.004","article-title":"FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes","volume":"22","author":"de Poel","year":"2023","journal-title":"J. Cyst. Fibros."},{"issue":"4","key":"10.1016\/j.biopha.2025.117862_bib82","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/procel\/pwad038","article-title":"Drug repurposing screening and mechanism analysis based on human colorectal cancer organoids","volume":"15","author":"Mao","year":"2024","journal-title":"Protein Cell"},{"issue":"4","key":"10.1016\/j.biopha.2025.117862_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112324","article-title":"Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer","volume":"42","author":"Mertens","year":"2023","journal-title":"Cell Rep."},{"issue":"2","key":"10.1016\/j.biopha.2025.117862_bib84","article-title":"A large-scale organoid-based screening platform to advance drug repurposing in pancreatic cancer","volume":"2","author":"Mainardi","year":"2022","journal-title":"Cell Genom."},{"issue":"4587","key":"10.1016\/j.biopha.2025.117862_bib85","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1126\/science.6823561","article-title":"Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis","volume":"219","author":"Langston","year":"1983","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.biopha.2025.117862_bib86","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0006-291X(86)80483-1","article-title":"Uptake of the neurotoxin 1-methyl-4-phenylpyridine (MPP+) by mitochondria and its relation to the inhibition of the mitochondrial oxidation of NAD+\u202f-linked substrates by MPP+","volume":"134","author":"Ramsay","year":"1986","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"9","key":"10.1016\/j.biopha.2025.117862_bib87","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1073\/pnas.0409713102","article-title":"Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and \u03b1-synuclein","volume":"102","author":"Fornai","year":"2005","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2025.117862_bib88","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1471-4159.2008.05651.x","article-title":"Modelling Parkinson-like neurodegeneration via osmotic minipump delivery of MPTP and probenecid","volume":"107","author":"Alvarez-Fischer","year":"2008","journal-title":"J. Neurochem."},{"issue":"1","key":"10.1016\/j.biopha.2025.117862_bib89","first-page":"19","article-title":"MPTP mouse models of Parkinson\u2019s disease: an update","volume":"1","author":"Meredith","year":"2011","journal-title":"J. Park. Dis."},{"issue":"5","key":"10.1016\/j.biopha.2025.117862_bib90","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1523\/JNEUROSCI.2010-15.2016","article-title":"Imaging dopamine and serotonin systems on MPTP monkeys: a longitudinal PET investigation of compensatory mechanisms","volume":"36","author":"Ballanger","year":"2016","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.biopha.2025.117862_bib91","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/jnc.15699","article-title":"Neurochemical, histological, and behavioral profiling of the acute, sub-acute, and chronic MPTP mouse model of Parkinson\u2019s disease","volume":"164","author":"Santoro","year":"2023","journal-title":"J. Neurochem."},{"key":"10.1016\/j.biopha.2025.117862_bib92","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jchemneu.2018.04.005","article-title":"Baseline striatal and nigral interneuronal protein levels in two distinct mice strains differ in accordance with their MPTP susceptibility","volume":"91","author":"Bhaduri","year":"2018","journal-title":"J. Chem. Neuroanat."},{"key":"10.1016\/j.biopha.2025.117862_bib93","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jchemneu.2016.01.001","article-title":"Differential expression of calbindin in nigral dopaminergic neurons in two mice strains with differential susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","volume":"76","author":"Vidyadhara","year":"2016","journal-title":"J. Chem. Neuroanat."},{"issue":"1","key":"10.1016\/j.biopha.2025.117862_bib94","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0006-8993(97)00531-3","article-title":"A chronic MPTP model reproducing the slow evolution of Parkinson\u2019s disease: evolution of motor symptoms in the monkey","volume":"766","author":"Bezard","year":"1997","journal-title":"Brain Res."},{"issue":"3","key":"10.1016\/j.biopha.2025.117862_bib95","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00702-017-1736-5","article-title":"Basal ganglia, movement disorders and deep brain stimulation: advances made through non-human primate research","volume":"125","author":"Wichmann","year":"2018","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.biopha.2025.117862_bib96","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0079-6123(10)84007-5","article-title":"The MPTP-lesioned non-human primate models of Parkinson\u2019s disease. Past, present, and future","volume":"184","author":"Fox","year":"2010","journal-title":"Prog. Brain Res."},{"issue":"3","key":"10.1016\/j.biopha.2025.117862_bib97","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1677\/JOE-09-0132","article-title":"Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson\u2019s disease","volume":"202","author":"Kim","year":"2009","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.biopha.2025.117862_bib98","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2021.697440","article-title":"Glucagon-like peptide-1 receptor agonist ameliorates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity through enhancing mitophagy flux and reducing \u03b1-synuclein and oxidative stress","volume":"14","author":"Lin","year":"2021","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.biopha.2025.117862_bib99","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.neuropharm.2018.02.012","article-title":"Two novel dual GLP-1\/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson\u2019s disease","volume":"133","author":"Feng","year":"2018","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.biopha.2025.117862_bib100","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s11011-021-00879-1","article-title":"Neuroprotective effects of liraglutide against inflammation through the AMPK\/NF-\u03baB pathway in a mouse model of Parkinson\u2019s disease","volume":"37","author":"Cao","year":"2022","journal-title":"Metab. Brain Dis."},{"issue":"1","key":"10.1016\/j.biopha.2025.117862_bib101","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s12640-021-00460-9","article-title":"Liraglutide regulates mitochondrial quality control system through PGC-1\u03b1 in a mouse model of Parkinson\u2019s disease","volume":"40","author":"Wu","year":"2022","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.biopha.2025.117862_bib102","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neuroscience.2015.06.054","article-title":"Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson\u2019s disease","volume":"303","author":"Liu","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.biopha.2025.117862_bib103","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.npep.2018.07.003","article-title":"Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson\u2019s disease mouse model","volume":"71","author":"Zhang","year":"2018","journal-title":"Neuropeptides"},{"key":"10.1016\/j.biopha.2025.117862_bib104","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejphar.2017.06.029","article-title":"A novel GLP-1\/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson\u2019s disease","volume":"812","author":"Yuan","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2025.117862_bib105","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.neuroscience.2014.07.046","article-title":"Neuroprotective effect of metformin in MPTP-induced Parkinson\u2019s disease in mice","volume":"277","author":"Patil","year":"2014","journal-title":"Neuroscience"},{"key":"10.1016\/j.biopha.2025.117862_bib106","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.neuropharm.2017.08.015","article-title":"Metformin lowers \u03b1-synuclein phosphorylation and upregulates neurotrophic factor in the MPTP mouse model of Parkinson\u2019s disease\u2019","volume":"125","author":"Katila","year":"2017","journal-title":"Neuropharmacology"},{"issue":"9","key":"10.1016\/j.biopha.2025.117862_bib107","doi-asserted-by":"crossref","first-page":"pyw047","DOI":"10.1093\/ijnp\/pyw047","article-title":"Metformin prevents dopaminergic neuron death in MPTP\/P-induced mouse model of Parkinson\u2019s disease via autophagy and mitochondrial ROS clearance","volume":"19","author":"Lu","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1\u20132","key":"10.1016\/j.biopha.2025.117862_bib108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2004.02.083","article-title":"Simvastatin prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice","volume":"1037","author":"Selley","year":"2005","journal-title":"Brain Res."},{"issue":"7","key":"10.1016\/j.biopha.2025.117862_bib109","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s10571-020-00804-7","article-title":"Simvastatin improves behavioral disorders and hippocampal inflammatory reaction by NMDA-mediated anti-inflammatory function in MPTP-treated mice","volume":"40","author":"Yan","year":"2020","journal-title":"Cell. Mol. Neurobiol."},{"issue":"1","key":"10.1016\/j.biopha.2025.117862_bib110","doi-asserted-by":"crossref","first-page":"831","DOI":"10.18632\/aging.202189","article-title":"Atorvastatin improves motor function, anxiety and depression by NOX2-mediated autophagy and oxidative stress in MPTP-lesioned mice","volume":"13","author":"Yan","year":"2020","journal-title":"Aging"},{"key":"10.1016\/j.biopha.2025.117862_bib111","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.brainres.2013.03.029","article-title":"Atorvastatin improves cognitive, emotional and motor impairments induced by intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats, an experimental model of Parkinson\u2019s disease","volume":"1513","author":"Castro","year":"2013","journal-title":"Brain Res."},{"issue":"3","key":"10.1016\/j.biopha.2025.117862_bib112","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s12640-017-9840-8","article-title":"Atorvastatin prevents early oxidative events and modulates inflammatory mediators in the striatum following intranasal 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats","volume":"33","author":"Marques","year":"2018","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.biopha.2025.117862_bib113","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.neuro.2015.03.012","article-title":"The neuroprotective effect of lovastatin on MPP(+)-induced neurotoxicity is not mediated by PON2","volume":"48","author":"Aguirre-Vidal","year":"2015","journal-title":"Neurotoxicology"},{"issue":"7","key":"10.1016\/j.biopha.2025.117862_bib114","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182019","article-title":"The phosphodiesterase inhibitor, ibudilast, attenuates neuroinflammation in the MPTP model of Parkinson\u2019s disease","volume":"12","author":"Schwenkgrub","year":"2017","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.biopha.2025.117862_bib115","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0014-2999(68)90164-7","article-title":"6-hydroxy-dopamine induced degeneration of central monoamine neurons","volume":"5","author":"Ungerstedt","year":"1968","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.biopha.2025.117862_bib116","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0014-5793(76)80974-X","article-title":"A rationale for the design of cell-specific toxic agents: the mechanism of action of 6-hydroxydopamine","volume":"72","author":"Rotman","year":"1976","journal-title":"FEBS Lett."},{"issue":"10","key":"10.1016\/j.biopha.2025.117862_bib117","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s00702-014-1185-3","article-title":"6-Hydroxydopamine impairs mitochondrial function in the rat model of Parkinson\u2019s disease: respirometric, histological, and behavioral analyses","volume":"121","author":"Kupsch","year":"2014","journal-title":"J. Neural Transm."},{"issue":"1","key":"10.1016\/j.biopha.2025.117862_bib118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.expneurol.2007.07.004","article-title":"Neuroinflammatory mechanisms in Parkinson\u2019s disease: potential environmental triggers, pathways, and targets for early therapeutic intervention","volume":"208","author":"Tansey","year":"2007","journal-title":"Exp. Neurol."},{"issue":"12","key":"10.1016\/j.biopha.2025.117862_bib119","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/jcb.25570","article-title":"\u2018Influence of 6-hydroxydopamine toxicity on \u03b1-synuclein phosphorylation, resting vesicle expression, and vesicular dopamine release","volume":"117","author":"Ganapathy","year":"2016","journal-title":"J. Cell. Biochem."},{"issue":"1","key":"10.1016\/j.biopha.2025.117862_bib120","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/ejn.16196","article-title":"Combining fibril-induced alpha-synuclein aggregation and 6-hydroxydopamine in a mouse model of Parkinson\u2019s disease and the effect of cerebral dopamine neurotrophic factor on the induced neurodegeneration","volume":"59","author":"Singh","year":"2024","journal-title":"Eur. J. Neurosci."},{"issue":"3","key":"10.1016\/j.biopha.2025.117862_bib121","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1006\/nbdi.1997.0151","article-title":"Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson\u2019s disease","volume":"4","author":"Bj\u00f6rklund","year":"1997","journal-title":"Neurobiol. Dis."},{"issue":"3","key":"10.1016\/j.biopha.2025.117862_bib122","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/0306-4522(95)00571-4","article-title":"Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by intrastriatal 6-hydroxydopamine in the rat","volume":"72","author":"Lee","year":"1996","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/j.biopha.2025.117862_bib123","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/0306-4522(94)90605-X","article-title":"Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat","volume":"59","author":"Sauer","year":"1994","journal-title":"Neuroscience"},{"issue":"3","key":"10.1016\/j.biopha.2025.117862_bib124","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/0306-4522(95)00066-R","article-title":"Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine\u2019","volume":"67","author":"Przedborski","year":"1995","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/j.biopha.2025.117862_bib125","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/jnr.21483","article-title":"Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of parkinson\u2019s disease","volume":"86","author":"Bertilsson","year":"2008","journal-title":"J. Neurosci. Res."},{"issue":"1","key":"10.1016\/j.biopha.2025.117862_bib126","doi-asserted-by":"crossref","first-page":"10722","DOI":"10.1038\/s41598-018-28449-z","article-title":"Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson\u2019s disease","volume":"8","author":"Chen","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2025.117862_bib127","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.brainres.2016.05.038","article-title":"Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson\u2019s disease","volume":"1646","author":"Hansen","year":"2016","journal-title":"Brain Res."},{"issue":"1","key":"10.1016\/j.biopha.2025.117862_bib128","first-page":"1428817","article-title":"DA5-CH and Semaglutide protect against neurodegeneration and reduce \u03b1-synuclein levels in the 6-OHDA Parkinson\u2019s disease rat model","volume":"2022","author":"Zhang","year":"2022","journal-title":"Park. Dis."},{"issue":"8","key":"10.1016\/j.biopha.2025.117862_bib129","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.4103\/1673-5374.389361","article-title":"Glucagon-like peptide-1\/glucose-dependent insulinotropic polypeptide dual receptor agonist DA-CH5 is superior to exendin-4 in protecting neurons in the 6-hydroxydopamine rat Parkinson model","volume":"16","author":"Zhang","year":"2021","journal-title":"Neural Regen. Res."},{"issue":"5","key":"10.1016\/j.biopha.2025.117862_bib130","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1007\/s11357-024-01116-0","article-title":"DPP-4 inhibitors sitagliptin and PF-00734,200 mitigate dopaminergic neurodegeneration, neuroinflammation and behavioral impairment in the rat 6-OHDA model of Parkinson\u2019s disease","volume":"46","author":"Yu","year":"2024","journal-title":"GeroScience"},{"issue":"6","key":"10.1016\/j.biopha.2025.117862_bib131","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020945","article-title":"Simvastatin prevents dopaminergic neurodegeneration in experimental parkinsonian models: the association with anti-inflammatory responses","volume":"6","author":"Yan","year":"2011","journal-title":"PLOS ONE"},{"issue":"1","key":"10.1016\/j.biopha.2025.117862_bib132","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.brainres.2005.03.016","article-title":"Simvastatin reverses the downregulation of dopamine D1 and D2 receptor expression in the prefrontal cortex of 6-hydroxydopamine-induced Parkinsonian rats","volume":"1045","author":"Wang","year":"2005","journal-title":"Brain Res."},{"key":"10.1016\/j.biopha.2025.117862_bib133","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.neuroscience.2014.02.031","article-title":"Simvastatin reverses the downregulation of M1\/4 receptor binding in 6-hydroxydopamine-induced parkinsonian rats: the association with improvements in long-term memory","volume":"267","author":"Wang","year":"2014","journal-title":"Neuroscience"},{"key":"10.1016\/j.biopha.2025.117862_bib134","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.brainres.2012.06.050","article-title":"Neuroprotective potential of atorvastatin and simvastatin (HMG-CoA reductase inhibitors) against 6-hydroxydopamine (6-OHDA) induced Parkinson-like symptoms","volume":"1471","author":"Kumar","year":"2012","journal-title":"Brain Res."},{"issue":"1","key":"10.1016\/j.biopha.2025.117862_bib135","first-page":"7427136","article-title":"A dual GLP-1\/GIP receptor agonist is more effective than liraglutide in the A53T mouse model of Parkinson\u2019s disease","volume":"2023","author":"Zhang","year":"2023","journal-title":"Park. Dis."},{"key":"10.1016\/j.biopha.2025.117862_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175029","article-title":"Cholecystokinin and glucagon-like peptide-1 analogues regulate intestinal tight junction, inflammation, dopaminergic neurons and \u03b1-synuclein accumulation in the colon of two Parkinson\u2019s disease mouse models","volume":"926","author":"Su","year":"2022","journal-title":"Eur. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.biopha.2025.117862_bib137","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/s41591-018-0051-5","article-title":"Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson\u2019s disease","volume":"24","author":"Yun","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2025.117862_bib138","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2021.113693","article-title":"An extended release GLP-1 analogue increases \u03b1-synuclein accumulation in a mouse model of prodromal Parkinson\u2019s disease\u2019","volume":"341","author":"Bergkvist","year":"2021","journal-title":"Exp. Neurol."},{"issue":"5","key":"10.1016\/j.biopha.2025.117862_bib139","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1111\/j.1471-4159.2008.05254.x","article-title":"Statins reduce neuronal alpha-synuclein aggregation in in Vitro models of Parkinson\u2019s disease","volume":"105","author":"Bar-On","year":"2008","journal-title":"J. Neurochem."},{"issue":"2","key":"10.1016\/j.biopha.2025.117862_bib140","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.expneurol.2009.11.015","article-title":"Lovastatin ameliorates alpha-synuclein accumulation and oxidation in transgenic mouse models of alpha-synucleinopathies","volume":"221","author":"Koob","year":"2010","journal-title":"Exp. Neurol."},{"issue":"7","key":"10.1016\/j.biopha.2025.117862_bib141","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-023-05977-9","article-title":"Statins suppress cell-to-cell propagation of \u03b1-synuclein by lowering cholesterol","volume":"14","author":"Min","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biopha.2025.117862_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2021.115859","article-title":"Roflupram attenuates \u03b1-synuclein-induced cytotoxicity and promotes the mitochondrial translocation of Parkin in SH-SY5Y cells overexpressing A53T mutant \u03b1-synuclein","volume":"436","author":"Zhong","year":"2022","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.biopha.2025.117862_bib143","article-title":"\u03b1-mangostin derivative 4e as a PDE4 inhibitor promote proteasomal degradation of alpha-synuclein in Parkinson\u2019s disease models through PKA activation","volume":"101","author":"Chen","year":"2022","journal-title":"Phytomed. Int. J. Phytother. Phytopharm."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225000563?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225000563?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T01:52:35Z","timestamp":1746755555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225000563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":143,"alternative-id":["S0753332225000563"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.117862","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An update on drug repurposing in Parkinson\u2019s disease: Preclinical and clinical considerations","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.117862","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117862"}}